Jennifer Nock

I'll research this attorney before drafting.

Let me verify the tracked case and her PTAB/Federal Circuit track record.

Let me confirm the Federal Circuit outcome and one of her argued appeals.

Jennifer P. Nock — Rothwell, Figg, Ernst & Manbeck, P.C. (Washington, D.C.)

Specialty / focus. Nock's practice centers on pharmaceutical and biologic patent litigation, including Hatch-Waxman small-molecule cases and BPCIA/biosimilar disputes, along with prosecution, post-grant proceedings, licensing, due-diligence opinions, and FDA-adjacent counseling. Her firm bio attributes this focus to a scientific background (A.M. in Chemistry, Harvard, where she worked in the Whitesides lab), and she has also handled matters in semiconductor manufacturing, consumer electronics, medical devices, chemical coatings, mechanical systems, apparel, cosmetics, and online education.

Side preference. The tracked case list shows a single appearance, on the defendant side (Amgen, as co-counsel), and nothing on the plaintiff side. That count appears to understate her activity, but it is directionally consistent with a defense-leaning docket. Web sources describe a mixed practice: she has represented both patent owners and challengers at the PTAB, and her firm bio notes brand and generic pharmaceutical clients — including, per a 2025 PTAB Bar Association spotlight, representation of a generic manufacturer in a Delaware Hatch-Waxman case. There is no indication she works the NPE/PAE plaintiff side.

Firm context. Nock has spent essentially her entire legal career at Rothwell Figg: summer associate in 2008, associate in 2010, and firm partner effective October 1, 2018. From 2012–2013 she clerked for then-Chief Judge Randall R. Rader on the U.S. Court of Appeals for the Federal Circuit. Before law school she spent roughly six years in university technology licensing (Tufts University).

Notable matters and outcomes. Her most prominent tracked case is Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (aflibercept/Eylea; ABP 938, marketed as Pavblu), part of the N.D. W. Va. aflibercept MDL. The district court denied Regeneron's preliminary injunction (Oct. 1, 2024), and the Federal Circuit affirmed on March 14, 2025 (No. 2024-2351), holding under Becton, Dickinson v. Tyco that the asserted '865 patent claims require a separate buffer component that Amgen's self-buffering formulation lacks. Amgen launched Pavblu at risk following the October 2024 denial of an injunction pending appeal. Other reported matters include Fresenius Kabi v. Coherus Biosciences (PGR2019-00064), where the PTAB denied institution against client Coherus's adalimumab formulation patent, and representation of patent owner AmorePacific in IPR2018-01516. Her bio also lists work on In re Copaxone 775 Patent Litigation, Teva v. Synthon, Braintree v. Breckenridge, Galderma v. Actavis, Sunovion v. Watson, Pfizer v. Cobalt, and the Federal Circuit appeal in Outdry Technologies v. Geox.

PTAB / IPR. Yes — post-grant work is a core part of her practice. Her firm bio lists IPR, PGR, and ex parte reexamination experience on both patent-owner and challenger sides, and she has been a named back-up or lead counsel in PTAB proceedings. She co-authored the Chambers Patent Litigation 2025 USA chapter (with Steven Lieberman and Joseph Hynds).

Bar / education. Admitted in D.C., Virginia, and to the USPTO; admitted to the Federal Circuit, D.D.C., E.D. Va., and the Supreme Court of Virginia. J.D., George Washington University Law School (2010, highest honors, Order of the Coif); A.M. Chemistry, Harvard; B.S. Chemistry and B.S. Physics, University of Richmond (summa cum laude).

Note: a distinct attorney named Jennifer Nock practices employment/public-law work in California; the profile above is the D.C.-based patent litigator. The single tracked appearance likely reflects incomplete docket coverage rather than the full scope of her litigation history.